Annalise.ai
Developer of medical imaging artificial intelligence for clinical triage and workflow optimization. Offers an integrated imaging-AI solution that analyzes chest radiographs and non-contrast head CT to identify time-sensitive and incidental findings, integrates with clinical imaging systems, and has received regulatory clearances and deployments across multiple countries.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
Comprehensive imaging AI triage for chest radiograph and head CT
Imaging-AI solution that analyzes chest radiographs and non-contrast head CT to identify a set of time-sensitive and incidental findings and present prioritized results within the clinical imaging workflow.
Comprehensive imaging AI triage for chest radiograph and head CT
Imaging-AI solution that analyzes chest radiographs and non-contrast head CT to identify a set of time-sensitive and incidental findings and present prioritized results within the clinical imaging workflow.
Services
Provision of radiology-specific foundational AI models for research use.
Deployment services to integrate imaging-AI outputs into existing PACS/RIS workflows and configurations for clinical use.
Provision of radiology-specific foundational AI models for research use.
Deployment services to integrate imaging-AI outputs into existing PACS/RIS workflows and configurations for clinical use.
Expertise Areas
- Medical imaging AI
- Clinical triage and radiology workflow automation
- Clinical validation and performance evaluation for imaging algorithms
- Regulatory clearance and health-technology designation for imaging software
Key Technologies
- Deep learning for medical imaging
- Multi-view and multi-modal imaging inference (CXR and CT)
- Worklist prioritization and triage algorithms
- Low-latency inference engines
News & Updates
Company reports $240 million in funding from global investors.
Reported Breakthrough Device designation from the U.S. regulatory authority for a specified imaging use case.
Reported New Technology Add-on Payment (NTAP) reimbursement eligibility for obstructive hydrocephalus and related Medicare payment references.
Company reports clinical clearance for use in 40+ countries for its imaging solutions.
Reported deployment figures include 3,500 clinicians at over 1,000 sites across four continents; regional adoption metrics cited include >35% of chest radiographs processed in a national health service, 100% of public Accident & Emergency departments in a regional system using the solution, >50% of radiologists in another national system having access, and 130+ hospitals across 45+ NHS Trusts.
Announcement of public availability of radiology-specific foundational models for research access.
Company reports $240 million in funding from global investors.
Reported Breakthrough Device designation from the U.S. regulatory authority for a specified imaging use case.
Reported New Technology Add-on Payment (NTAP) reimbursement eligibility for obstructive hydrocephalus and related Medicare payment references.
Company reports clinical clearance for use in 40+ countries for its imaging solutions.
Reported deployment figures include 3,500 clinicians at over 1,000 sites across four continents; regional adoption metrics cited include >35% of chest radiographs processed in a national health service, 100% of public Accident & Emergency departments in a regional system using the solution, >50% of radiologists in another national system having access, and 130+ hospitals across 45+ NHS Trusts.
Announcement of public availability of radiology-specific foundational models for research access.